These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 11309732)

  • 1. Clinical and molecular basis of transfusion-induced immunomodulation: summary of the proceedings of a state-of-the-art conference.
    Blajchman MA; Dzik S; Vamvakas EC; Sweeney J; Snyder EL
    Transfus Med Rev; 2001 Apr; 15(2):108-35. PubMed ID: 11309732
    [No Abstract]   [Full Text] [Related]  

  • 2. [Special features of blood transfusion to children].
    Salonvaara M
    Duodecim; 2004; 120(7):860-5. PubMed ID: 15154307
    [No Abstract]   [Full Text] [Related]  

  • 3. Management of late CML relapse.
    Flowers M
    Biol Blood Marrow Transplant; 2008 Jul; 14(7):847-8. PubMed ID: 18541206
    [No Abstract]   [Full Text] [Related]  

  • 4. Photodynamic purging of alloreactive T cells for adoptive immunotherapy after haploidentical stem cell transplantation.
    Perruccio K; Topini F; Tosti A; Carotti A; Aloisi T; Aversa F; Martelli MF; Velardi A
    Blood Cells Mol Dis; 2008; 40(1):76-83. PubMed ID: 17977031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cytokines and immunomodulation in blood transfusion: a permanent challenge].
    Iturbe Hernńandez T; Cornudella Lacasa R; Moreno Chulilla JA; Guitiérrez Martín M
    Med Clin (Barc); 1999 Dec; 113(19):758. PubMed ID: 10680135
    [No Abstract]   [Full Text] [Related]  

  • 6. [Cellular immunotherapy in advanced carcinoma of the breast by means of tumour antigen-specific autologous T-memory bone marrow cells as a phase I study].
    Schütz F
    Zentralbl Gynakol; 2004 Dec; 126(6):365-7. PubMed ID: 15570551
    [No Abstract]   [Full Text] [Related]  

  • 7. Leucodepletion and immune response mechanisms.
    Semple JW
    Vox Sang; 2004 Jul; 87 Suppl 2():136-8. PubMed ID: 15209898
    [No Abstract]   [Full Text] [Related]  

  • 8. B-cell enrichment and infusion in CD4+/CD8+ T-cell depleted products for donor innate immune lymphocyte infusion: is risk of EBV-associated lymphocyte post transplantation lymphoproliferative disease a concern?
    Lamb LS; Sande J
    Bone Marrow Transplant; 2008 Jun; 41(11):995-6. PubMed ID: 18278072
    [No Abstract]   [Full Text] [Related]  

  • 9. Delayed lymphocyte infusion in children given SCT.
    Klingebiel T; Bader P;
    Bone Marrow Transplant; 2008 Jun; 41 Suppl 2():S23-6. PubMed ID: 18545238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of treatment with donor lymphocytes and interleukin-2 in a patient with two posttransplantation recurrences of acute myeloid leukemia].
    Zhelnova EI; Mendeleeva LP; Liubimova LS; Demidova IA; Parovichnikova EN; Poreshina LP; Kut'ina RM; Shpakova AP; Kaplanskaia IB; Kalinin NN; Savchenko VG
    Ter Arkh; 2007; 79(8):67-9. PubMed ID: 17926475
    [No Abstract]   [Full Text] [Related]  

  • 11. [Donor lymphocyte infusions as adoptive immunotherapy in patients with relapsed hematologic neoplasms post-allogenic transplant of hematopoietic progenitor cells].
    Riera L; Koziner B
    Medicina (B Aires); 2000; 60(2):259-69. PubMed ID: 10962823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence that FK 506 may abrogate suppressor cell activity induced by blood transfusion.
    Propper DJ; Woo J; Macleod AM; Thomson AW
    Transplant Proc; 1991 Dec; 23(6):3310-1. PubMed ID: 1721446
    [No Abstract]   [Full Text] [Related]  

  • 13. Adoptive cellular immunotherapy of cancer: an overview.
    Stevenson HC
    Immunol Ser; 1989; 48():1-18. PubMed ID: 2488314
    [No Abstract]   [Full Text] [Related]  

  • 14. Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer.
    Gomez GG; Hutchison RB; Kruse CA
    Cancer Treat Rev; 2001 Dec; 27(6):375-402. PubMed ID: 11908930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic cell-mediated immunotherapy of leukemia with immune donor lymphocytes to upregulate antitumor effects and downregulate antihost responses.
    Ji YH; Weiss L; Zeira M; Abdul-Hai A; Reich S; Schuger L; Slavin S
    Bone Marrow Transplant; 2003 Sep; 32(5):495-504. PubMed ID: 12942096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion.
    Orsini E; Bellucci R; Alyea EP; Schlossman R; Canning C; McLaughlin S; Ghia P; Anderson KC; Ritz J
    Cancer Res; 2003 May; 63(10):2561-8. PubMed ID: 12750280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing immune responses for cancer therapy.
    Xue SA; Stauss HJ
    Cell Mol Immunol; 2007 Jun; 4(3):173-84. PubMed ID: 17601371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amelioration of graft-versus-host disease following bowel transplantation with recipient specific leukocyte transfusion.
    Xiao F; Foster PF; Sankary HN; Kociss K; Williams JW
    Transplant Proc; 1992 Jun; 24(3):1192-3. PubMed ID: 1604582
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical-scale single-step CD4(+) and CD8(+) cell depletion for donor innate lymphocyte infusion (DILI).
    Smetak M; Kimmel B; Birkmann J; Schaefer-Eckart K; Einsele H; Wilhelm M; Kunzmann V
    Bone Marrow Transplant; 2008 Apr; 41(7):643-50. PubMed ID: 18037935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Massive transfusion--state of the art.
    Weinstabl C
    Acta Anaesthesiol Scand Suppl; 1996; 109():79-80. PubMed ID: 8901956
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.